The Development and Regulation of Psychedelic Medicines

Nash, Jonathan (2017) The Development and Regulation of Psychedelic Medicines. In: Socio-Legal Studies Association Annual Conference 2017, 5th - 7th April 2017, Newcastle University, UK.

[img] Slideshow (Powerpoint)
SLSA.pptx - Published Version
Restricted to Registered users only

Download (6MB) | Request a copy
[img] Text (Slideshow)
SLSA.pdf - Published Version
Restricted to Registered users only

Download (3MB) | Request a copy


Psychedelic research into mental disorders is currently re-emerging after a near 40-year morass and appears to offer a new paradigm of treatment for civilians and veterans suffering from mental disorder and/or addiction.
The paper introduces the recent rebirth of psychedelic research at a small number of US and European universities such as Johns Hopkins, New Mexico, Zurich, UCLA, NYU, Imperial College London as well as at non-academic bodies with research into substances such as MDMA, psilocybin, LSD, THC and CBD in marijuana, ketamine, DMT (found in ayahuasca) and ibogaine. The legal impediments to psychedelic research and regulation are discussed including international drug conventions, drug scheduling, medicine regulation and the patent system. The paper considers the controversial nature of the research and its implications which could drive significant medical change through new forms of treatment for mental disorder and addiction.

Item Type: Conference or Workshop Item (Lecture)
Subjects: B200 Pharmacology, Toxicology and Pharmacy
M200 Law by Topic
Department: Faculties > Business and Law > Northumbria Law School
Depositing User: Jonathan Nash
Date Deposited: 04 Sep 2017 09:58
Last Modified: 02 Mar 2018 20:16

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics

Policies: NRL Policies | NRL University Deposit Policy | NRL Deposit Licence